Immunotherapy (Checkpoint Inhibitors)
Tecentriq (atezolizumab) in Saudi Arabia — Regulatory and Supply Information
Anti-PD-L1 monoclonal antibody for extensive-stage small cell lung cancer (with carboplatin + etoposide), NSCLC, hepatocellular carcinoma (with bevacizumab), urothelial cancer and alveolar soft-part sarcoma. Dosed 1200 mg q3w, 840 mg q2w or 1680 mg q4w.

Prescription-only medicine. No pricing is published on this page. Prescription-medicine pricing is not advertised to the public in this market.
This page is informational and is not an advertisement, a promotional communication, or medical advice. It does not offer any medicine for sale to the public. Treatment decisions belong to your treating physician.
What this medicine is
- Active ingredient
- atezolizumab
- Marketing authorisation holder
- Roche
- Therapeutic class
- Immunotherapy (Checkpoint Inhibitors)
Presentations and dosage forms
- 840 mg / 14 mL vial
- 1200 mg / 20 mL vial (IV infusion)
Storage, cold chain and handling
Refrigerate 2–8°C, protect from light, do not freeze.
The regulatory route in Saudi Arabia
Medicines in Saudi Arabia are regulated by the Saudi Food and Drug Authority (SFDA). Every product described on this site is a prescription-only medicine, supplied against a valid prescription from a treating physician and dispensed through licensed channels. Nothing on this page is an offer to sell to the public.
Controlled medicines carried by travellers run through the SFDA's Controlled Drugs System (CDS) at cds.sfda.gov.sa. The SFDA published its Guideline for Clearance Permit of Controlled Drugs for Travelers on 14 August 2025, which sets out the electronic clearance request process.
Saudi Arabia updated its personal-import and prescription rules in December 2024. Confirm the current requirements directly with the SFDA before applying.
The SFDA publishes registration data for locally manufactured and non-local human medicines as open data. It does not publish a medicine price dataset, so any site presenting an "official SFDA price" for a specific product is not drawing on a published SFDA source. The SFDA also publishes drug circulars, withdrawal notices and current shortage information in Arabic — worth checking first, because a national shortage is the most common reason a prescribed medicine cannot be dispensed locally.
The process, step by step
- Create an account on the Controlled Drugs System (CDS) at cds.sfda.gov.sa.
- Submit an electronic clearance request containing the patient details and the trip details.
- Upload the prescription, the medical report and proof of identity.
- Specify the trade name, active ingredient, concentration and quantity of each medicine.
- Track the request status, which is shown as Submitted, Completed, Rejected or Incomplete.
Documentation typically required
- A valid prescription from the treating physician, naming the trade name, active ingredient, concentration and quantity
- A medical report describing the diagnosis and the treatment plan
- Proof of identity for the patient (and for the accompanying person, where relevant)
- Travel details, where the medicine is being carried by a traveller
- For a hospital or clinic: the establishment licence and the request of the responsible pharmacist
Official sources
Search terms for this medicine
The same molecule is searched under several names. All of the following refer to the same product:
- Tecentriq
- atezolizumab
- تيسنتريك
- أتيزوليزوماب
- Tecentriq Saudi Arabia
- تيسنتريك المملكة العربية السعودية
- atezolizumab SFDA
- Tecentriq prescription
- تيسنتريك وصفة طبية
Frequently asked questions
Prescription-based enquiry
If you hold a valid prescription from a treating physician in Saudi Arabia, you can send us the prescription details and we will reply with the regulatory and documentation position for that specific product. We do not publish pricing for Saudi Arabia and we do not sell to the public.
Send a prescription-based enquiryBackground reading
- Why medicines cost less in Türkiye
- How to verify a medicine is genuine
- WHO falsified medicine alerts
- Named patient supply
- For healthcare professionals
- Import guide — Saudi Arabia
- Hospital & procurement — Saudi Arabia
- Saudi Arabia medicines
- Tecentriq — Kuwait
- Tecentriq — Bahrain
- Tecentriq — United Arab Emirates
- Tecentriq — Qatar
- Tecentriq — Azerbaijan
Related medicines
Medically reviewed by Pharmacy Remedy Pharmacovigilance & Compliance Desk · Last updated: 2026-07-29 · Saudi Food and Drug Authority
For healthcare professionals
Prescribers, hospital and specialty pharmacies, oncology centres and procurement departments: named patient supply, documentation and the sourcing workflow.